AIM ImmunoTech Inc. (AIM) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-10

Key Insights

AIM ImmunoTech has entered into an amendment to its existing Equity Distribution Agreement with Maxim Group LLC, removing the limitation on the amount of shares that can be sold under the at-the-market public offering.
The company is filing a supplement to the prospectus supplement to increase the number of shares that may be offered and sold in the at-the-market public offering.
This indicates that AIM ImmunoTech is seeking to raise additional capital through the sale of its common stock, which could be used for various corporate purposes.

Want the newest filings?

This analysis covers the filing from 2026-04-10. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-06

AIM ImmunoTech Inc. has filed a Certificate of Designation to create a new series of preferred stock, the Series G Convertible Preferred Stock, which can be converted into common stock at a price of $1.00 per share.
The company has completed a rights offering, selling 1,842 units consisting of Series G Preferred Stock and Class G Warrants, raising gross proceeds of approximately $1.8 million.
The Series G Preferred Stock has certain conversion limitations, anti-dilution provisions, and liquidation preferences that investors should be aware of.

Filed: 2026-02-05

AIM ImmunoTech is conducting a Phase I/II open-label study of Durvalumab (Imfinzi) and Rintatolimod (Ampligen) in pancreatic cancer patients with stable disease post-FOLFIRINOX treatment.
The company has provided an interim clinical progress update on the DURIPANC study, indicating ongoing activities and developments.
AIM has furnished its February 2026 corporate presentation, which likely contains additional details on the company's strategic initiatives and pipeline progress.

Filed: 2026-01-20

AIM ImmunoTech is making changes to its Class E and Class F common stock purchase warrants, potentially impacting shareholders.
The company is involved in multiple clinical trials evaluating its drug Ampligen for the treatment of viral diseases, cancers, and immune-deficiency disorders, though no assurances are given regarding the outcomes.
The filing includes cautionary statements regarding forward-looking statements and risk factors that investors should review carefully.

Other reports for AIM ImmunoTech Inc.

Annual Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.